Mixed data from two Threshold cancer trials

California-based Threshold Pharmaceuticals has released an update on its glufosfamide program. According to the company's release, a Phase II trial of the drug for soft tissue sarcoma "provided evidence of clinical activity." Threshold will continue trials of the drug for this indication, but said that dosing will have to be adjusted in later studies. The news was not so good from the ovarian cancer trial. The company has decided to drop glufosfamide due to a lack of efficacy and enrollment challenges.

In October, Threshold cut its staff and expenses after reporting disappointing data from Phase II trial of glufosfamide for small cell lung cancer. The drug is also undergoing Phase III trials for pancreatic cancer, and is in Phase I trials for the treatment of solid tumors.

- see this release from Threshold for more

Suggested Articles

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

The data position Leo to file for approval of the Dupixent rival in atopic dermatitis next year.

The treatment staved off cancer for a median of 16.4 months and shrank tumors in 61% of patients with HER2-positive breast cancer.